More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
CAMBRIDGE, Mass., Jan. 03, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients. To learn more about Editas Medicine, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
[email protected]
